PMID- 36922492
OWN - NLM
STAT- MEDLINE
DCOM- 20230322
LR  - 20230418
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Mar 15
TI  - Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody 
      responses against the receptor-binding domain.
PG  - 1451
LID - 10.1038/s41467-023-37128-1 [doi]
LID - 1451
AB  - The immunogenicity of mRNA vaccines has not been well studied when compared to 
      different vaccine modalities in the context of additional boosters. Here we show 
      that longitudinal analysis reveals more sustained SARS-CoV-2 spike 
      receptor-binding domain (RBD)-binding IgG titers with the breadth to 
      antigenically distinct variants by the S-268019-b spike protein booster compared 
      to the BNT162b2 mRNA homologous booster. The durability and breadth of 
      RBD-angiotensin-converting enzyme 2 (ACE2) binding inhibitory antibodies are 
      pronounced in the group without systemic adverse events (AEs) after the 
      S-268019-b booster, leading to the elevated neutralizing activities against 
      Omicron BA.1 and BA.5 variants in the stratified group. In contrast, BNT162b2 
      homologous booster elicited antibodies to spike N-terminal domain in proportion 
      to the AE scores. High-dimensional immune profiling identifies early CD16(+) 
      natural killer cell dynamics with CCR3 upregulation, as one of the correlates for 
      the distinct anti-RBD antibody responses by the S-268019-b booster. Our results 
      illustrate the combinational effects of heterologous booster on the immune 
      dynamics and the durability and breadth of recalled anti-RBD antibody responses 
      against emerging virus variants.
CI  - (c) 2023. The Author(s).
FAU - Takano, Tomohiro
AU  - Takano T
AUID- ORCID: 0000-0003-4267-1147
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Sato, Takashi
AU  - Sato T
AUID- ORCID: 0000-0002-2676-3781
AD  - Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
FAU - Kotaki, Ryutaro
AU  - Kotaki R
AUID- ORCID: 0000-0001-7965-1671
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Moriyama, Saya
AU  - Moriyama S
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Fukushi, Shuetsu
AU  - Fukushi S
AD  - Department of Virology I, National Institute of Infectious Diseases, Tokyo, 
      162-8640, Japan.
FAU - Shinoda, Masahiro
AU  - Shinoda M
AD  - Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
FAU - Kabasawa, Kiyomi
AU  - Kabasawa K
AD  - Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
FAU - Shimada, Nagashige
AU  - Shimada N
AD  - Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
FAU - Kousaka, Mio
AU  - Kousaka M
AD  - Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
FAU - Adachi, Yu
AU  - Adachi Y
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Onodera, Taishi
AU  - Onodera T
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Terahara, Kazutaka
AU  - Terahara K
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Isogawa, Masanori
AU  - Isogawa M
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan.
FAU - Matsumura, Takayuki
AU  - Matsumura T
AUID- ORCID: 0000-0003-1760-3484
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan. matt@niid.go.jp.
FAU - Shinkai, Masaharu
AU  - Shinkai M
AD  - Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan. shinkai050169@gmail.com.
FAU - Takahashi, Yoshimasa
AU  - Takahashi Y
AUID- ORCID: 0000-0001-6342-4087
AD  - Research Center for Drug and Vaccine Development, National Institute of 
      Infectious Diseases, Tokyo, 162-8640, Japan. ytakahas@niid.go.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230315
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (BNT162 Vaccine)
RN  - 0 (Immunoglobulin G)
RN  - 0 (S-268019-b COVID-19 vaccine)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - 0 (COVID-19 Vaccines)
RN  - COVID-19 vaccine booster shot
SB  - IM
MH  - Humans
MH  - Antibodies, Neutralizing
MH  - Antibodies, Viral
MH  - *Antibody Formation
MH  - BNT162 Vaccine
MH  - *COVID-19
MH  - Immunoglobulin G
MH  - SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus/genetics
MH  - *COVID-19 Vaccines/immunology
PMC - PMC10016167
COIS- The authors declare no competing interests.
EDAT- 2023/03/17 06:00
MHDA- 2023/03/21 06:00
PMCR- 2023/03/15
CRDT- 2023/03/16 00:53
PHST- 2022/08/30 00:00 [received]
PHST- 2023/03/03 00:00 [accepted]
PHST- 2023/03/16 00:53 [entrez]
PHST- 2023/03/17 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/03/15 00:00 [pmc-release]
AID - 10.1038/s41467-023-37128-1 [pii]
AID - 37128 [pii]
AID - 10.1038/s41467-023-37128-1 [doi]
PST - epublish
SO  - Nat Commun. 2023 Mar 15;14(1):1451. doi: 10.1038/s41467-023-37128-1.